News
Beacon Therapeutics announces phase 2 interim 6 months data from DAWN trial of Laru-zova: London Friday, May 9, 2025, 18:00 Hrs [IST] Beacon Therapeutics Holdings Limited, a leadi ...
Strong Clinical Evidence Supports Use of the Suprachoroidal Platform in Expanding the Standard of Care for the Treatment of Multiple Macular Diseases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback